Suppr超能文献

分子成像中的临床试验:遵循方案的重要性。

Clinical trials in molecular imaging: the importance of following the protocol.

作者信息

Trembath LisaAnn, Opanowski Adam

机构信息

1Trembath Consulting, LLC, Middleton, Wisconsin, USA.

出版信息

J Nucl Med Technol. 2011 Jun;39(2):63-9. doi: 10.2967/jnmt.110.083691. Epub 2011 May 12.

Abstract

Nuclear medicine technologists and investigators who perform imaging procedures in clinical trials often have not received training on clinical research regulations, such as Title 21, part 312, of the Code of Federal Regulations or Good Clinical Practices. These regulations directly affect implementation of the therapeutic or imaging protocol. Lack of understanding of the regulatory expectations in clinical research can lead to unintended errors or omissions in critical data that are needed for development of a new drug. One common error is not following the protocol exactly as written, or modifying the imaging parameters in some way as to make the data nonstandard from site to site. These errors and omissions are a source of delay in the development of new imaging and therapeutic products. Although not following the protocol does not result in criminal penalties per se, errors and omissions can lead to regulatory consequences such as warning letters to the investigator or sponsor, which if not resolved can lead to barring a site or investigator from participation in any future research trials. Pharmaceutical sponsors, device sponsors, and federal granting agencies such as the National Cancer Institute enter into contracts with imaging sites under the expectation that the investigator and all research staff know and understand clinical research regulations. This article is intended to teach imaging personnel what any sponsor (pharmaceutical, device, or federal agency) is expecting from research imaging and how lack of understanding of Good Clinical Practices and federal regulations can impede the optimal success of a research study. After reading this article, nuclear medicine technologists should be able to understand the importance of following the clinical trial protocol to exact specifications, create a list of questions that should be answered by the sponsor or trial organizers before patient enrollment, describe Form FDA 1572, and describe the terms protocol, protocol deviation, protocol violation, and protocol exception.

摘要

在临床试验中进行成像程序的核医学技术人员和研究人员通常未接受过临床研究法规方面的培训,例如《联邦法规法典》第21编第312部分或《药物临床试验质量管理规范》。这些法规直接影响治疗或成像方案的实施。对临床研究中的法规要求缺乏了解可能会导致新药研发所需关键数据出现意外错误或遗漏。一个常见的错误是未严格按照书面方案进行操作,或以某种方式修改成像参数,致使各研究地点的数据不标准。这些错误和遗漏是新型成像和治疗产品研发延迟的一个原因。虽然不遵循方案本身不会导致刑事处罚,但错误和遗漏可能会带来监管后果,如向研究者或申办者发出警告信,若问题得不到解决,可能会导致某个研究地点或研究者被禁止参与未来的任何研究试验。制药申办者、器械申办者以及美国国立癌症研究所等联邦资助机构与成像研究地点签订合同,期望研究者和所有研究人员了解并理解临床研究法规。本文旨在教导成像人员任何申办者(制药、器械或联邦机构)对研究成像的期望是什么,以及对《药物临床试验质量管理规范》和联邦法规缺乏了解如何会阻碍研究的最佳成功。阅读本文后,核医学技术人员应能够理解严格按照临床试验方案的精确规范操作的重要性,列出在患者入组前应由申办者或试验组织者回答的问题清单,描述FDA 1572表格,并描述方案、方案偏离、方案违规和方案例外等术语。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验